Last reviewed 2026-04-20 · How we verify

Reference formulation (Treatment B) (reference-formulation-treatment-b)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Headache
• Nasopharyngitis
• Diarrhoea
• Nausea
• Cardiac disorders
• Abdominal pain
• Vomiting
• HEADACHE
• Tachycardia
• Dizziness
• Throat irritation
• Abnormal faeces

Key clinical trials

• A Study in Healthy Men to Find Out How Different Doses of BI 3009947 Are Tolerated and How Different Formulations or Food Influence How BI 3009947 is Taken up Into the Blood (PHASE1)
• Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets (PHASE1)
• A Clinical Study of the Effect of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-041) (PHASE1)
• A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma (PHASE1)
• A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults (PHASE1)
• Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants (PHASE3)
• Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma (PHASE3)
• A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Reference formulation (Treatment B) CI brief — competitive landscape report
• Reference formulation (Treatment B) updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI